CompoSecure, Inc. Files 8-K Report

TL;DR

CompoSecure (CMPO) filed an 8-K on 12/12/25. Details TBD.

AI Summary

On December 12, 2025, CompoSecure, Inc. filed an 8-K report. The filing indicates a change in the company's status or operations, though specific details of the event are not provided in the provided text. The company, formerly known as Roman DBDR Tech Acquisition Corp., is incorporated in Delaware and headquartered in Somerset, New Jersey.

Why It Matters

This 8-K filing signals a material event for CompoSecure, Inc., requiring disclosure to investors and the public. Investors should review the full filing for details on the reported event.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which typically reports material events, but the specific nature of the event is not detailed in the provided text, necessitating further investigation.

Key Numbers

• 001-39687 — Commission File Number (Identifies the company's SEC filing history)
• 852749902 — IRS Employer Identification No. (Tax identification number for the company)

Key Players & Entities

• CompoSecure, Inc. (company) — Registrant
• Roman DBDR Tech Acquisition Corp. (company) — Former Name
• December 12, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Somerset, New Jersey (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value CMPO NYSE Indicate by c
• $3.953 billion — ggregate consideration of approximately $3.953 billion in cash and 55,297,297 shares of the Co
• $18.50 — ny Common Stock, at a purchase price of $18.50 per share, for an aggregate purchase pr
• $1.96 billion — gregate purchase price of approximately $1.96 billion. In connection with the transactions c
• $1.3 — 2017 Duravant LLC Warburg Pincus LLC $1.3 ~13x December 2017 Husky Injection
• $3.9 — ms International Ltd. Platinum Equity $3.9 11.6x (1) January 2018 ProMach Grou
• $2.2 — roup, Inc Leonard Green & Partners LP $2.2 ~14x July 2019 Milacron Holdings Co
• $2.0 — cron Holdings Corp. Hillenbrand, Inc. $2.0 9.6x July 2019 Bosch Packaging Tec
• $1.0 — ology (Syntegon) CVC Capital Partners $1.0 ~18x July 2020 IMA Group BC Partne
• $4.2 — July 2020 IMA Group BC Partners LLP $4.2 ~17x October 2021 Duravant LLC Car
• $5.9 — 2021 Duravant LLC Carlyle Group Inc. $5.9 ~18x November 2022 Liquibox Sealed
• $1.2 — vember 2022 Liquibox Sealed Air Corp $1.2 13.5x (2) May 2023 ProMach Group In
• $4.8 — D Partners & Leonard Green Partners LP $4.8 ~15x May 2023 Schenck Process Food
• $0.7 — rformance Materials Hillenbrand, Inc. $0.7 10.7x (3) July 2023 IMA Group BDT
• $6.9 — ly 2023 IMA Group BDT & MSD Partners $6.9 ~19x June 2024 Marel hf. JBT Corpo

Filing Documents

• tm2533351d1_8k.htm (8-K) — 83KB
• 0001104659-25-120723.txt ( ) — 255KB
• cmpo-20251212.xsd (EX-101.SCH) — 3KB
• cmpo-20251212_lab.xml (EX-101.LAB) — 33KB
• cmpo-20251212_pre.xml (EX-101.PRE) — 22KB
• tm2533351d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events As previously disclosed, on November 2, 2025, CompoSecure, Inc., a Delaware corporation ("CompoSecure" or the "Company"), and certain of its subsidiaries entered into a Share Purchase Agreement (the "Transaction Agreement") with Husky Technologies Limited ("Husky"), Platinum Equity Advisors, LLC ("Platinum Equity"), certain entities affiliated with Platinum Equity and certain members of Husky management (collectively, the "Sellers"). Under the terms of the Transaction Agreement, the Company will combine with Husky for aggregate consideration of approximately $3.953 billion in cash and 55,297,297 shares of the Company's Class A Common Stock ("Common Stock"), par value $0.0001 per share, subject to the adjustments set forth in the Transaction Agreement. On November 2, 2025, concurrently with the execution of the Transaction Agreement, the Company also entered into purchase agreements (together, the "Purchase Agreements") with certain investors named therein (collectively, the "Investors"), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 106,056,083 shares of Company Common Stock, at a purchase price of $18.50 per share, for an aggregate purchase price of approximately $1.96 billion. In connection with the transactions contemplated by the Transaction Agreement (the "Transactions"), the Company filed a definitive proxy statement (the "Proxy Statement") with the U.S. Securities and Exchange Commission (the "SEC") on November 24, 2025. The special meeting of the CompoSecure shareholders (the "Special Meeting") will be held virtually on December 23, 2025, at 10:00 a.m., Eastern Time, to act on a proposal to approve the issuance of CompoSecure Common Stock pursuant to the terms of the Transaction Agreement and the Purchase Agreements, as disclosed in the Proxy Statement. Since the filing of the Company's Proxy Statement, several purported shareholders of the Company have sent demand le

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking letters and complaints relating to the Transactions, the timing and completion of the Transactions, expected benefits, future plans, expectations and opportunities, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others: (i) the risk that the Transactions may not be completed in a timely manner or at all; (ii) the failure to obtain required approvals, including regulatory approvals and the Company Stockholder Approval; (iii) the occurrence of any event that could give rise to termination of the Share Purchase Agreement; (iv) the effect of the announcement, pendency or consummation of the Transactions on the parties' business relationships, operations, financial and accounting matters; (v) risks that the expected benefits of the Transactions, including financial projections, estimates and outlook, may not be fully realized or may take longer to realize than expected; (vi) risks related to financing the Transactions; (vii) costs related to the Transactions; (viii) potential litigation and/or regulatory actions relating to the Transactions, including the demand letters and Complaints described herein, and otherwise; (ix) general economic, market, industry and competitive conditions; and (x) other risks and uncertainties described in CompoSecure's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q, which identify and address other important risks and uncertainties that could cause actual events and results to differ materially from th

View Full Filing

View this 8-K filing on SEC EDGAR